Selected Publications

Academic Article

Year Title Altmetric
2021 Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathyJournal of Autoimmunity.  118. 2021
2021 IgA vasculitis with nephritis: update of pathogenesis with clinical implicationsPediatric Nephrology2021
2020 Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylationScientific Reports.  10. 2020
2020 Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by AntibodiesiScience.  23. 2020
2020 A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis 2020
2020 Upregulated proteoglycan-related signaling pathways in fluid flow shear stress-treated podocytes 2020
2020 Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteinsExpert Review of Proteomics.  17:275-296. 2020
2020 Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?Journal of Nephrology.  33:307-316. 2020
2020 TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathyKidney International.  97:340-349. 2020
2019 Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With NephritisKidney International Reports.  4:1717-1724. 2019
2019 Distinct Fcα receptor N-glycans modulate the binding affinity to immunoglobulin A (IgA) antibodiesJournal of Biological Chemistry.  294:13995-14008. 2019
2019 Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression (PLoS One (2019) 14:2 (e0212254) DOI: 10.1371/journal.pone.0212254)PLoS ONE.  14. 2019
2019 IgA1 hinge-region clustered glycan fidelity is established early during semi-ordered glycosylation by GalNAc-T2Glycobiology.  29:543-556. 2019
2019 Glycosylation in health and diseaseNature Reviews Nephrology.  15:346-366. 2019
2019 Health-related quality of life in glomerular diseaseKidney International.  95:1209-1224. 2019
2019 CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular DiseaseAmerican Journal of Kidney Diseases.  73:218-229. 2019
2019 Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progressionPLoS ONE.  14. 2019
2019 Defining HIV-1 envelope N-glycan microdomains through site-specific heterogeneity profilesJournal of Virology.  93. 2019
2019 Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1Journal of the American Society of Nephrology.  30:2017-2026. 2019
2019 The emerging role of complement proteins as a target for therapy of IgA nephropathyFrontiers in Immunology.  10. 2019
2018 Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN StudyKidney International Reports.  3:1373-1384. 2018
2018 Secondary IgA nephropathyKidney International.  94:674-681. 2018
2018 Aberrant Glycosylation of the IgA1 Molecule in IgA NephropathySeminars in Nephrology.  38:461-476. 2018
2018 Funkce endotelu, její vztah k arteriální hypertenzi a možnosti její modulace 2018
2018 Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients 2018
2018 Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathyPLoS ONE.  13. 2018
2017 Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysisNephrology Dialysis Transplantation.  32:2079-2089. 2017
2017 What insights can proteomics give us into IgA nephropathy (Berger’s disease)?Expert Review of Proteomics.  14:645-647. 2017
2017 Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantationJournal of the American Society of Nephrology.  28:1943-1950. 2017
2017 A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunctionJournal of the American Society of Nephrology.  28:1306-1313. 2017
2017 GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathwayPLoS Genetics.  13. 2017
2017 An update on the treatment of IgA nephropathyAktuality V Nefrologii.  23:60-62. 2017
2017 Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA NephropathyKidney International Reports.  2:1194-1207. 2017
2017 Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy ControlsInternational Journal of Nephrology.  2017. 2017
2016 IgA nephropathy - research-generated questions 2016
2016 IgA nephropathy enigmaClinical Immunology.  172:72-77. 2016
2016 Markers for the progression of IgA nephropathyJournal of Nephrology.  29:535-541. 2016
2016 The origin and activities of IgA1-containing immune complexes in IGA nephropathyFrontiers in Immunology.  7. 2016
2016 IgA nephropathyNature Reviews Disease Primers.  2. 2016
2016 Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?Disease Markers.  2016. 2016
2016 Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathyJournal of the American Society of Nephrology.  27:3278-3284. 2016
2016 Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic StudyDisease Markers.  2016. 2016
2015 New Insights into the Pathogenesis of IgA Nephropathy.Kidney Diseases.  1:8-18. 2015
2015 Current understanding of the role of complement in IgA nephropathyJournal of the American Society of Nephrology.  26:1503-1512. 2015
2015 N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathyNephrology Dialysis Transplantation.  30:234-238. 2015
2015 The serum very-low-density lipoprotein serves as a restriction factor against hepatitis C virus infectionJournal of Virology.  89:6782-6791. 2015
2015 Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathyJournal of the American Society of Nephrology.  26:1195-1204. 2015
2014 The kinetics of glomerular deposition of nephritogenic IgAPLoS ONE.  9. 2014
2014 Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogensNature Genetics.  46:1187-1196. 2014
2014 Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infectionAIDS Research and Therapy.  11. 2014
2014 Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune DiseaseJournal of Immunology Research.  2014. 2014
2014 The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathyJournal of Immunology.  193:317-326. 2014
2014 Enzymatic sialylation of IgA1 O-glycans: Implications for studies of IgA nephropathyPLoS ONE.  9. 2014
2014 The genetics and immunobiology of IgA nephropathyJournal of Clinical Investigation.  124:2325-2332. 2014
2014 A panel of serum biomarkers differentiates IgA nephropathy from other renal diseasesPLoS ONE.  9. 2014
2014 Immune profile of IgA-dominant diffuse proliferative glomerulonephritisClinical Kidney Journal.  7:479-483. 2014
2014 Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapyPLoS ONE.  9. 2014
2014 Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymesJournal of Biological Chemistry.  289:5330-5339. 2014
2014 Development of animal models of human IgA nephropathyDrug Discovery Today: Disease Models.  11:5-11. 2014
2014 HIV-1 envelope glycan moieties modulate HIV-1 transmissionJournal of Virology.  88:14258-14267. 2014
2014 Humoral Immune Responses to HIV in the Mucosal Secretions and Sera of HIV-Infected WomenAmerican Journal of Reproductive Immunology.  71:600-607. 2014
2014 Origin of galactose-deficient immunoglobulin G in gingival crevicular fluid in periodontitisJournal of Periodontology.  85:1779-1785. 2014
2014 Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathyClinical and Experimental Nephrology.  18:770-777. 2014
2013 Biomarkers in IgA nephropathy: Relationship to pathogenetic hitsExpert Opinion on Medical Diagnostics.  7:615-627. 2013
2013 Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: Role of cysteine alkylation during sample processing 2013
2013 Pathogenesis of immunoglobulin A nephropathyCurrent Opinion in Nephrology and Hypertension.  22:287-294. 2013
2013 Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinomaCellular and Molecular Life Sciences.  70:829-839. 2013
2013 Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organsNephrology Dialysis Transplantation.  28:320-326. 2013
2013 Pathogenesis of immunoglobulin a nephropathy: Recent insight from genetic studiesAnnual Review of Medicine.  64:339-356. 2013
2013 IgA nephropathy: Molecular mechanisms of the diseaseAnnual Review of Pathology: Mechanisms of Disease.  8:217-240. 2013
2012 The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathyKidney International.  82:1284-1296. 2012
2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.Clinical Nephrology.  78:465-469. 2012
2012 Endothelial nitric oxide synthase inhibits the development of autoimmune-mediated vasculitis in miceArthritis and Rheumatism.  64:4114-4124. 2012
2012 In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cellsResults in Immunology.  2:166-172. 2012
2012 Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexesAmerican Journal of Pathology.  181:1338-1347. 2012
2012 The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progressionKidney International.  82:790-796. 2012
2012 Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathyInternational Journal of Nephrology.  2012. 2012
2012 Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathyJournal of the American Society of Nephrology.  23:1579-1587. 2012
2012 Implementation of proteomic biomarkers: Making it workEuropean Journal of Clinical Investigation.  42:1027-1036. 2012
2012 Development of a model of early-onset IgA nephropathyJournal of the American Society of Nephrology.  23:1364-1374. 2012
2012 Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysisPLoS Genetics.  8. 2012
2012 Glycosylation of IgA1 and pathogenesis of IgA nephropathySpringer Seminars in Immunopathology.  34:365-382. 2012
2012 Induction of IgA deposits and glomerulonephritis by IgA rheumatoid factorJournal of the American Society of Nephrology.  23:371-373. 2012
2012 Naturally occurring structural isomers in serum IgA1 O -glycosylationJournal of Proteome Research.  11:692-702. 2012
2012 Production of N-acetylgalactosaminyl-transferase 2 (GalNAc-T2) fused with secretory signal Igκ in insect cellsProtein Expression and Purification.  81:175-180. 2012
2012 Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathyClinical Nephrology.  78:465-469. 2012
2012 Erratum: Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy (Journal of Clinical Investigation (2011) 121, 10 (3991-4002) DOI: 10.1172/JCI45563)Journal of Clinical Investigation.  122:778. 2012
2011 Membrane-assisted online renaturation for automated microfluidic lectin blottingJournal of the American Chemical Society.  133:19610-19613. 2011
2011 Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosisKidney International.  80:1252-1254. 2011
2011 Current view of the pathogenesis of IgA nephropathy and possibilities for causal therapyAlergie -Praha-.  13:268-274. 2011
2011 APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathyJournal of the American Society of Nephrology.  22:1991-1996. 2011
2011 IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cellsNephrology Dialysis Transplantation.  26:3451-3457. 2011
2011 Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathyJournal of Clinical Investigation.  121:3991-4002. 2011
2011 The pathophysiology of IgA nephropathyJournal of the American Society of Nephrology.  22:1795-1803. 2011
2011 Aberrant glycosylation of iga1 and anti-glycan antibodies in iga nephropathy: Role of mucosal immune system 2011
2011 Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyClinical Journal of the American Society of Nephrology.  6:1903-1911. 2011
2011 Reevaluation of the mucosa-bone marrow Axis in IgA nephropathy with animal models 2011
2011 Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrinInfection and Immunity.  79:2440-2450. 2011
2011 Galactosylation of serum IgA1 O-glycans in celiac diseaseJournal of Clinical Immunology.  31:74-79. 2011
2011 Genome-wide association study identifies susceptibility loci for IgA nephropathyNature Genetics.  43:321-329. 2011
2011 Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritisKidney International.  80:79-87. 2011
2010 Clustered O-glycans of IgA1: Defining macro- and microheterogeneity by use of electron capture/transfer dissociationMolecular and Cellular Proteomics.  9:2545-2557. 2010
2010 Galactose-deficient IgA1 in African Americans with IgA nephropathy: Serum levels and heritabilityClinical Journal of the American Society of Nephrology.  5:2069-2074. 2010
2010 Genetic studies of IgA nephropathy: Past, present, and futurePediatric Nephrology.  25:2257-2268. 2010
2010 Recommendations for biomarker identification and qualification in clinical proteomicsScience Translational Medicine.  2. 2010
2010 Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: A comparative binding study.Biochemistry.  49:5671-5682. 2010
2010 Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognitionJournal of Biological Chemistry.  285:20860-20869. 2010
2010 Involvement of envelope-glycoprotein glycans in HIV-1 biology and infectionArchivum Immunologiae et Therapiae Experimentalis.  58:191-208. 2010
2010 Antibody-mediated protection and the mucosal immune system of the genital tract: Relevance to vaccine designJournal of Reproductive Immunology.  85:81-85. 2010
2010 Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1Nephrology Dialysis Transplantation.  25:1708-1713. 2010
2010 Tissue distribution and biological activities of immune complexes are determined by their size and compositionNephrology Dialysis Transplantation.  25:1007. 2010
2010 Comparison of methods for profiling O-glycosylation: Human proteome organisation human disease glycomics/proteome initiative multi-institutional study of IgA1Molecular and Cellular Proteomics.  9:719-727. 2010
2010 Comprehensive human urine standards for comparability and standardization in clinical proteome analysis 2010
2010 Erratum: Pathogenesis of Henoch-Schönlein purpura nephritis (Pediatric Nephrology DOI: 10.1007/s00467/009-1230-x)Pediatric Nephrology.  25:179. 2010
2010 Familial IgA nephropathy in southeastern KentuckyClinical Nephrology.  73:115-121. 2010
2010 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney diseaseMolecular and Cellular Proteomics.  9:2424-2437. 2010
2010 Pathogenesis of Henoch-Schönlein purpura nephritisPediatric Nephrology.  25:19-26. 2010
2009 Application of proteomic analysis to renal disease in the clinic 2009
2009 Sources of urinary proteins and their analysis by urinary proteomics for the detection of biomarkers of disease 2009
2009 Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminansBiochemistry.  48:8312-8321. 2009
2009 Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developmentsMass Spectrometry Reviews.  28:703-724. 2009
2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityJournal of Clinical Investigation.  119:1668-1677. 2009
2008 Toll-like receptor 9 affects severity of IgA nephropathyJournal of the American Society of Nephrology.  19:2384-2395. 2008
2008 Analysis of IgA1 N-glycosylation and its contribution to FcαRI bindingBiochemistry.  47:11285-11299. 2008
2008 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics 2008
2008 Urinary proteomics in diabetes and CKDJournal of the American Society of Nephrology.  19:1283-1290. 2008
2008 Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathyJournal of the American Society of Nephrology.  19:1008-1014. 2008
2008 Treatment of IgA nephropathy 2008
2008 Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responsesVaccine.  26:1541-1551. 2008
2008 Elucidation of the antimicrobial mechanism of mutacin 1140Biochemistry.  47:3308-3314. 2008
2008 IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1Journal of Clinical Investigation.  118:629-639. 2008
2008 Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of iga nephropathyKidney and Blood Pressure Research.  31:29-37. 2008
2008 IgA Glycosylation and IgA Immune Complexes in the Pathogenesis of IgA NephropathySeminars in Nephrology.  28:78-87. 2008
2008 Overexpression of innate immune response genes in a model of recessive polycystic kidney diseaseKidney International.  73:63-76. 2008
2008 Response to 'Overexpression of complement-component genes in Han:SPRD rats a model of polycystic kidney disease'Kidney International.  73:1325. 2008
2007 Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the futureJournal of Proteome Research.  6:4549-4555. 2007
2007 Electrophoretic methods for analysis of urinary polypeptides in lgA-associated renal diseasesELECTROPHORESIS.  28:4469-4483. 2007
2007 Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpuraPediatric Nephrology.  22:2067-2072. 2007
2007 Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: Implications for IgA nephropathy 2007
2007 Isolation of flagellated bacteria implicated in Crohn's diseaseInflammatory Bowel Diseases.  13:1191-1201. 2007
2007 Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseasesWorld Journal of Urology.  25:467-476. 2007
2007 High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine 2007
2007 Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levelsKidney International.  71:1148-1154. 2007
2007 The genetics of IgA nephropathyNature Reviews Nephrology.  3:325-338. 2007
2007 IgA nephropathy and henoch-schoenlein purpura nephritis: Aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cellsContributions to Nephrology.  157:134-138. 2007
2007 IgA nephropathy: A clinical overviewContributions to Nephrology.  157:19-26. 2007
2007 IgA nephropathy: Characterization of IgG antibodies specific for galactose-deficient IgA1Contributions to Nephrology.  157:129-133. 2007
2007 IgA nephropathy: Current views of immune complex formationContributions to Nephrology.  157:56-63. 2007
2007 Identification and Characterization of CMP-NeuAc:GalNAc-IgA1 α2,6-Sialyltransferase in IgA1-producing CellsJournal of Molecular Biology.  369:69-78. 2007
2007 CE - A multifunctional application for clinical diagnosisELECTROPHORESIS.  28:1407-1417. 2007
2007 Advances in urinary proteome analysis and biomarker discoveryJournal of the American Society of Nephrology.  18:1057-1071. 2007
2007 Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteinsMolecular Immunology.  44:2598-2604. 2007
2007 Clinical proteomics: A need to define the field and to begin to set adequate standards 2007
2006 High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MSProteomics.  6:5615-5627. 2006
2006 IgA-containing immune complexes in the urine of IgA nephropathy patientsNephrology Dialysis Transplantation.  21:2478-2484. 2006
2006 Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separationELECTROPHORESIS.  27:2111-2125. 2006
2006 Immunoglobulin A and renal diseases 2006
2005 Urinary IgA in IgA nephropathy patients - A new finding which support diagnosis of IgA nephropathyAktuality V Nefrologii.  11:11-17. 2005
2005 Heterogeneity of IgG glycosylation in adult periodontal diseaseJournal of Dental Research.  84:897-901. 2005
2005 Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometryJournal of Biological Chemistry.  280:19136-19145. 2005
2005 Increased levels of galactose-deficient IgG in sera of HIV-1-infected individualsAIDS.  19:381-389. 2005
2005 IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cellsKidney International.  67:504-513. 2005
2004 Glycosylation and Size of IgA1 Are Essential for Interaction with Mesangial Transferrin Receptor in IgA NephropathyJournal of the American Society of Nephrology.  15:622-634. 2004
2004 IgA nephropathy: An updateCurrent Opinion in Nephrology and Hypertension.  13:171-179. 2004
2003 Structure and dynamics of the lantibiotic mutacin 1140Biochemistry.  42:10372-10384. 2003
2002 The Fap1 fimbrial adhesin is a glycoprotein: Antibodies specific for the glycan moiety block the adhesion of Streptococcus parasanguis in an in vitro tooth model 2002
2002 IgA nephropathy pathogenetic importance of immunoglobulin a glycosylation and clinical presentation 2002
2002 Interactions of human mesangial cells with IgA and IgA-containing immune complexesKidney International.  62:465-475. 2002
2001 Progress in molecular and genetic studies of IgA nephropathyJournal of Clinical Immunology.  21:310-327. 2001
2001 Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin IIFEMS Microbiology Letters.  195:139-144. 2001
2001 Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II.FEMS Microbiology Letters.  195:139-144. 2001
2000 Heterogeneity of O-glycosylation in the hinge region of human IgA1Molecular Immunology.  37:1047-1056. 2000
2000 Expression of the recombinant human immunoglobulin J chain in Escherichia coliMolecular Immunology.  37:133-140. 2000
2000 Biochemical structural analysis of the lantibiotic mutacin IIJournal of Biological Chemistry.  275:15845-15850. 2000
2000 Production, distribution, and structure of human IgA molecules 2000
2000 Detection of antimicrobials in bee products with activity against viridans streptococciJournal of Alternative and Complementary Medicine.  6:383-389. 2000
2000 IgA1 glycosylation and the pathogenesis of IgA nephropathyAmerican Journal of Kidney Diseases.  35:551-554. 2000
2000 Invited Lecture 3:Production, distribution, and structure of human IgA molecules 2000
1999 Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodiesJournal of Clinical Investigation.  104:73-81. 1999
1999 Progress in the pathogenesis of IgA nephropathy. 1999
1999 The specific genes for lantibiotic mutacin II biosynthesis in Streptococcus mutans T8 are clustered and can be transferred en blocApplied and Environmental Microbiology.  65:1356-1360. 1999
1998 Sequence analysis of mutA and mutM genes involved in the biosynthesis of the lantibiotic mutacin II in Streptococcus mutansGene.  206:37-43. 1998
1998 Diacylglycerol kinase is involved in regulation of expression of the lantibiotic mutacin II of Streptococcus mutansJournal of Bacteriology.  180:167-170. 1998
1998 Extraction, assay, and analysis of antimicrobials from plants with activity against dental pathogens (Streptococcus sp.)Journal of Alternative and Complementary Medicine.  4:39-45. 1998
1998 Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutansInfection and Immunity.  66:2743-2749. 1998
1998 Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategyApplied and Environmental Microbiology.  64:2335-2340. 1998
1997 Expression and protein engineering of the lantibiotic mutacin II 1997
1997 Structure and activity of the lantibiotic mutacin II. Evidence for two domains? 1997
1997 Microbially-produced peptides having potential application to the prevention of dental cariesInternational Journal of Antimicrobial Agents.  9:95-105. 1997
1997 Nitrogen source regulates expression of alanine dehydrogenase isoenzymes in Streptomyces avermitilis in a chemically defined mediumCanadian Journal of Microbiology.  43:189-193. 1997
1997 Ribosomal RNA (rrn) operons in Streptococcus mutans and nucleotide sequence of tRNA(Pro) gene associated with rrnB 1997
1997 Transposon mutagenesis: Cloning of chromosomal DNA from the site of Tn916 insertion using polymerase chain reactionBiotechnology Letters.  11:51-54. 1997
1996 Detection of modified amino acids in lantibiotic peptide mutacin II by chemical derivatization and electrospray ionization-mass spectroscopic analysisAnalytical Biochemistry.  236:358-360. 1996
1996 Characterization of PepB, a group B streptococcal oligopeptidaseInfection and Immunity.  64:3401-3406. 1996
1996 Programmed cell death [3]Science.  274:20-21. 1996
1995 Mutacin II, a bactericidal lantibiotic from Streptococcus mutansAntimicrobial Agents and Chemotherapy.  39:2656-2660. 1995
1994 Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutansJournal of Bacteriology.  176:4316-4320. 1994
1993 Production of avermectin A2a and monoglycosides A2a and B2a by a strain of Streptomyces avermitilisFolia Microbiologica.  38:367-370. 1993
1993 Instability of the production of avermectins, sporulation, and pigmentation in Streptomyces avermitilisCanadian Journal of Microbiology.  39:265-267. 1993
1992 N-Acetyl-isoleucine in Streptomyces avermitilisFEMS Microbiology Letters.  94:85-87. 1992
1992 Screening for a new generation of anthelminthic compounds. In vitro selection of the nematode Caenorhabditis elegans for ivermectin resistanceFolia Microbiologica.  37:237-238. 1992
1992 Nitrogen regulation of fatty acids and avermectins biosynthesis in Streptomyces avermitilisFEMS Microbiology Letters.  93:57-61. 1992
1992 Enzymes of ammonium assimilation in Streptomyces avermitilisFolia Microbiologica.  37:261-266. 1992
1991 Isolation of erythromycin A N-oxide and pseudoerythromycin A hemiketal from fermentation broth of Saccharopolyspora erythraea by thin-layer and high-performance liquid chromatography 1991
1990 Biosynthesis of avermectins and lipids in Streptomyces avermitilisFEMS Microbiology Letters.  70:291-294. 1990
1988 A rapid screening of Streptomycesavermitilis production strainsBiotechnology Letters.  2:47-52. 1988
1988 Nitrogen regulation of avermectins biosynthesis in Streptomyces avermitilis in a chemically defined medium 1988


Year Title Altmetric
2016 Heterogeneity of aberrant O-glycosylation of IgA1 in IgA nephropathy.  53-68. 2016
2015 IgA Nephropathy and Related Diseases.  2023-2038. 2015
2009 IgA immune-complex.  177-191. 2009

Principal Investigator On

  • Molecular Basis of Pathogenicity of IgA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by RETROPHIN, INC. 2018 - 2021
  • Genetics of IgA Nephropathy by Integrative Network-Based Association Studies  awarded by Columbia University 2015 - 2021
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC. 2018 - 2020
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by Columbia University 2014 - 2020
  • Molecular Basis of Pathogenicity of IgA1-containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2019
  • Aptamers-Based Arrays for Detection of Pathogenic IgA 1 O-Glycoforms in IgA Nephropathy  awarded by Columbia University 2016 - 2018
  • IgA Nephropathy and the Role of Clustered Glycosylation Initiation by GaINAc-Transferases  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2015 - 2016
  • Private Grant  awarded by Pfizer Pharmaceuticals 2013 - 2015
  • Elucidating IgA Nephropathy Through Genetic Studies of IgA1 Glycosylation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2014
  • New Animal Model for Studies of Mucosal Immunity and IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2013
  • Urinary Polypeptide Biomakers for IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2012
  • Molecular Basis of Pathogenicity of 1gA1-Containing Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012
  • IgA1-Secreting B Cell Lines: A Novel Tool for Studies of IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2011
  • Investigator On

  • Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2020 - 2025
  • Interdisciplinary Training In Kidney-Related Research  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2019 - 2024
  • PRedoctoral Interdisciplinary Training in Renal Physiology and MEdIcIne (PRIME)  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2016 - 2022
  • Abnormal STAT3 Signaling and Aberrant O-Glycosylation of IgA1 in IgA Nephropathy  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2021
  • Streptococcus Pneumoniae Capsule Inhibitor  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2018 - 2020
  • GDCN Clinical Center - Advancing Clinical Research in Primary Glomerular Diseases  awarded by University of North Carolina at Chapel Hill 2014 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • IgA Nephropathy: Interventions with Generation of Nephritogenic Immune Complexes  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2014 - 2018
  • Analytical Tools for the Analysis of Clustered O-Glycans in Clinical Samples  awarded by National Institute of General Medical Sciences/NIH/DHHS 2011 - 2016
  • Education And Training

  • Doctor of Philosophy Level Degree in Cell / Cellular and Molecular Biology, 1990
  • Master of Sciences or Mathematics in Physiology, Pathology and Related Sciences, Charles University in Prague 1987
  • Bachelor of Science or Mathematics in Biology, Charles University in Prague 1985
  • Full Name

  • Jan Novak